---
title: "Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target Raised to $567.00 at Bank of America"
description: "Bank of America has raised its price target for Vertex Pharmaceuticals (NASDAQ: VRTX) from $555.00 to $567.00, maintaining a \"buy\" rating. This new target suggests a potential upside of 15.08% from th"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/234059414.md"
published_at: "2025-04-01T12:26:52.000Z"
---

# Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target Raised to $567.00 at Bank of America

> Bank of America has raised its price target for Vertex Pharmaceuticals (NASDAQ: VRTX) from $555.00 to $567.00, maintaining a "buy" rating. This new target suggests a potential upside of 15.08% from the stock's previous close. Other analysts have also adjusted their ratings, with a consensus rating of "Moderate Buy" and an average price target of $508.65. Vertex's stock opened at $492.69, with a market cap of $126.52 billion. The company reported an EPS of $3.54 for the last quarter, missing estimates by $0.45.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) had its price objective boosted by equities research analysts at Bank of America from $555.00 to $567.00 in a report issued on Monday,Benzinga reports. The brokerage currently has a "buy" rating on the pharmaceutical company's stock. Bank of America's price objective would indicate a potential upside of 15.08% from the stock's previous close.

Get **Vertex Pharmaceuticals** alerts:

-   MaxCyte: Building the Future of Cell and Gene Therapy Innovation

A number of other equities research analysts have also recently issued reports on VRTX. Cantor Fitzgerald reissued an "overweight" rating and issued a $480.00 target price on shares of Vertex Pharmaceuticals in a research report on Tuesday, February 11th. Barclays upped their price target on shares of Vertex Pharmaceuticals from $435.00 to $467.00 and gave the stock an "equal weight" rating in a report on Tuesday, February 11th. Piper Sandler lowered their price objective on shares of Vertex Pharmaceuticals from $535.00 to $533.00 and set an "overweight" rating for the company in a research report on Monday, January 27th. Truist Financial raised their target price on Vertex Pharmaceuticals from $460.00 to $520.00 and gave the company a "buy" rating in a report on Tuesday, February 11th. Finally, Wells Fargo & Company cut Vertex Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $460.00 price target for the company. in a report on Thursday, January 30th. Ten investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $508.65.

**View Our Latest Stock Report on VRTX**

## Vertex Pharmaceuticals Stock Performance

-   Vertex's Pain Drug: Big Pharma's Next Major Success?

Shares of VRTX opened at $492.69 on Monday. The firm has a 50-day moving average of $476.45 and a 200-day moving average of $463.64. The company has a market cap of $126.52 billion, a PE ratio of -223.95, a price-to-earnings-growth ratio of 2.11 and a beta of 0.41. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.69 and a quick ratio of 2.35. Vertex Pharmaceuticals has a one year low of $377.85 and a one year high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last released its quarterly earnings data on Monday, February 10th. The pharmaceutical company reported $3.54 EPS for the quarter, missing analysts' consensus estimates of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%. As a group, equities analysts forecast that Vertex Pharmaceuticals will post 15.63 earnings per share for the current year.

## Insider Buying and Selling

-   2 Gene-Editing Stocks Positioned for a Strong Comeback in 2025

In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 244 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $455.06, for a total value of $111,034.64. Following the transaction, the executive vice president now directly owns 67,695 shares of the company's stock, valued at approximately $30,805,286.70. The trade was a 0.36 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP David Altshuler sold 3,231 shares of the firm's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $500.00, for a total transaction of $1,615,500.00. Following the sale, the executive vice president now directly owns 26,512 shares of the company's stock, valued at approximately $13,256,000. This trade represents a 10.86 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 4,315 shares of company stock valued at $2,121,012 over the last quarter. Insiders own 0.20% of the company's stock.

## Hedge Funds Weigh In On Vertex Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in VRTX. Public Sector Pension Investment Board grew its stake in Vertex Pharmaceuticals by 14.2% in the third quarter. Public Sector Pension Investment Board now owns 11,244 shares of the pharmaceutical company's stock valued at $5,229,000 after acquiring an additional 1,400 shares during the period. Captrust Financial Advisors grew its position in Vertex Pharmaceuticals by 2.2% in the 3rd quarter. Captrust Financial Advisors now owns 14,409 shares of the pharmaceutical company's stock valued at $6,701,000 after purchasing an additional 307 shares during the period. Kestra Investment Management LLC increased its stake in Vertex Pharmaceuticals by 28.7% during the 3rd quarter. Kestra Investment Management LLC now owns 2,315 shares of the pharmaceutical company's stock valued at $1,077,000 after purchasing an additional 516 shares in the last quarter. Benjamin Edwards Inc. raised its holdings in Vertex Pharmaceuticals by 4,913.5% during the third quarter. Benjamin Edwards Inc. now owns 6,668 shares of the pharmaceutical company's stock worth $3,101,000 after buying an additional 6,535 shares during the last quarter. Finally, Beck Capital Management LLC lifted its stake in shares of Vertex Pharmaceuticals by 1.9% in the third quarter. Beck Capital Management LLC now owns 2,004 shares of the pharmaceutical company's stock valued at $932,000 after buying an additional 38 shares in the last quarter. Institutional investors own 90.96% of the company's stock.

## Vertex Pharmaceuticals Company Profile

(Get Free Report)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

## Read More

-   Five stocks we like better than Vertex Pharmaceuticals
-   Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
-   Lululemon Pulls Back Into Classic Dip-Buying Opportunity
-   How to Read Stock Charts for Beginners
-   Cintas Delivers Earnings Beat, Signals More Growth Ahead
-   Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
-   Analysts Say These 4 Low P/E Consumer Cyclical Stocks Are Buys

*This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.*

## Should You Invest $1,000 in Vertex Pharmaceuticals Right Now?

Before you consider Vertex Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vertex Pharmaceuticals wasn't on the list.

While Vertex Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

### Related Stocks

- [VRTX.US - Vertex Pharma](https://longbridge.com/en/quote/VRTX.US.md)
- [VERX.US - Vertex](https://longbridge.com/en/quote/VERX.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 福泰制药｜8-K：2025 财年 Q4 营收 31.9 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/275807197.md) |
| 在全球疼痛市场中，新机制和新模式存在显著的机会 | 全球疼痛市场为创新提供了重大机会，特别是在开发非成瘾性替代阿片类药物方面。目前，全球批准的疼痛药物中有 98% 是仿制药，治疗选择缺乏多样性。Vertex Pharmaceuticals 的 Journavx 最近获得批准，标志着一个突破， | [Link](https://longbridge.com/en/news/275921122.md) |
| OS Therapies 为复发性、已完全切除的肺转移性骨肉瘤中的 OST-HER2 提供全球监管更新 \| OSTX 股票新闻 | OS Therapies Inc.（纽约证券交易所代码：OSTX）已提供其免疫疗法 OST-HER2 的全球监管更新，该疗法旨在预防复发性肺转移性骨肉瘤。该公司计划在 2026 年第一季度之前提交额外的生物标志物数据，并完成在英国和欧洲的市 | [Link](https://longbridge.com/en/news/276114753.md) |
| Canbridge Pharmaceuticals Inc 将发行总计 8400 万股认购股份 | Canbridge Pharmaceuticals Inc 将发行总计 8400 万股认购股份 | [Link](https://longbridge.com/en/news/276022079.md) |
| Sionna Therapeutics 在古根海姆峰会上规划了 2026 年中期的囊性纤维化催化剂，并重点介绍了 NBD1 稳定剂 | Sionna Therapeutics 在 2026 年古根海姆新兴前景生物技术峰会上展示了其开发下一代囊性纤维化疗法的战略，重点关注 NBD1 稳定性。首席执行官 Mike Cloonan 强调了 NBD1 作为靶点的重要性，特别是对于影 | [Link](https://longbridge.com/en/news/276001201.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
